Skip to main content

Research Repository

Advanced Search

All Outputs (131)

KSR1 regulates BRCA1 degradation and inhibits breast cancer growth (2014)
Journal Article
Stebbing, J., Zhang, H., Xu, Y., Lit, L. C., Green, A., Grothey, A., …Giamas, G. (2015). KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. Oncogene, 34(16), 2103-2114. https://doi.org/10.1038/onc.2014.129

Kinase suppressor of Ras-1 (KSR1) facilitates signal transduction in Ras-dependent cancers, including pancreatic and lung carcinomas but its role in breast cancer has not been well studied. Here, we demonstrate for the first time it functions as a tu... Read More about KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.

Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study (2014)
Journal Article
Aleskandarany, M. A., Negm, O. H., Green, A. R., Ahmed, M. A. H., Nolan, C. C., Tighe, P. J., …Rakha, E. A. (2014). Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Research and Treatment, 145(2), 339-348. https://doi.org/10.1007/s10549-014-2927-5

Epithelial mesenchymal transition (EMT), as defined by loss of epithelial characteristics and gain of a mesenchymal phenotype, has been reported in vivo although the occurrence of events remains unclear. This study aims at exploration of EMT portrait... Read More about Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.

Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer (2014)
Journal Article
Jerjees, D. A., Alabdullah, M., Green, A. R., Alshareeda, A., Macmillan, R. D., Ellis, I. O., & Rakha, E. A. (2014). Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. Breast Cancer Research and Treatment, 145(2), 317-330. https://doi.org/10.1007/s10549-014-2941-7

The definition of Luminal-B subclass of breast cancer (BC) varies in literature. In this study, we have compared the proliferation status; assessed using KI67 labeling index (KI67-LI), and HER2-expression in estrogen receptor positive (ER+) BC to ass... Read More about Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer (2014)
Journal Article
Green, A. R., Barros, F. F., Abdel-Fatah, T. M., Moseley, P., Nolan, C. C., Durham, A. C., …Ellis, I. O. (2014). HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Research and Treatment, 145(1), 33-44. https://doi.org/10.1007/s10549-014-2925-7

Human epidermal growth factor receptor 2 (HER2) plays an important role in breast cancer progression and provides predictive information for response to targeted therapy including trastuzumab although this is limited. Downstream pathways, such as PI3... Read More about HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer (2014)
Journal Article
Rakha, E., Soria, D., Green, A. R., Lemetre, C., Powe, D. G., Nolan, C. C., …Ellis, I. O. (2014). Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. British Journal of Cancer, 110(7), https://doi.org/10.1038/bjc.2014.120

Current management of breast cancer (BC) relies on risk stratification based on well-defined clinicopathologic factors. Global gene expression profiling studies have demonstrated that BC comprises distinct molecular classes with clinical relevance. I... Read More about Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.

SUMOylation proteins in breast cancer (2014)
Journal Article
Alshareeda, A. T., Negm, O. H., Green, A. R., Nolan, C., Tighe, P., Albarakati, N., …Rakha, E. A. (2014). SUMOylation proteins in breast cancer. Breast Cancer Research and Treatment, 144(3), 519-530. https://doi.org/10.1007/s10549-014-2897-7

Small Ubiquitin-like Modifier proteins (or SUMO) modify the function of protein substrates involved in various cellular processes including DNA damage response (DDR). It is becoming apparent that dysregulated SUMO contribute to carcinogenesis by affe... Read More about SUMOylation proteins in breast cancer.

C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? (2013)
Journal Article
Ho-Yen, C. M., Green, A. R., Brentnall, A. R., Rakha, E. A., Ellis, I. O., Kermorgant, S., & Jones, J. L. (2014). C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. Cancer, 120(2), 163-171. https://doi.org/10.1002/cncr.28386

BACKGROUND Basal‐like (BL) breast cancer is an aggressive form of breast cancer with limited treatment options. Recent work has identified BL breast cancer as a biologically distinct form of triple‐negative breast cancer, with a worse outlook. The... Read More about C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?.

A quantifier-based fuzzy classification system for breast cancer patients (2013)
Journal Article
Soria, D., Garibaldi, J. M., Green, A. R., Powe, D. G., Nolan, C. C., Lemetre, C., …Ellis, I. O. (2013). A quantifier-based fuzzy classification system for breast cancer patients. Artificial Intelligence in Medicine, 58(3), https://doi.org/10.1016/j.artmed.2013.04.006

Objectives:Recent studies of breast cancer data have identified seven distinct clinical phenotypes (groups) using immunohistochemical analysis and a range of different clustering techniques. Consensus between unsupervised classification algorithms ha... Read More about A quantifier-based fuzzy classification system for breast cancer patients.

Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy (2011)
Journal Article
Storr, S. J., Woolston, C. M., Barros, F. F., Green, A. R., Shehata, M., Chan, S. Y., …Martin, S. G. (2011). Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. International Journal of Cancer, 129(7), 1773-1780. https://doi.org/10.1002/ijc.25832

The calpain family, and their endogenous inhibitor calpastatin, has been implicated in cancer progression, and recent in vitro data have indicated a role in trastuzumab resistance. The aims of our study were to examine expression levels of calpastati... Read More about Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy.

A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients (2010)
Journal Article
Soria, D., Garibaldi, J. M., Ambrogi, F., Green, A. R., Powe, D., Rakha, E., …Ellis, I. O. (2010). A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Computers in Biology and Medicine, 40(3), https://doi.org/10.1016/j.compbiomed.2010.01.003

Single clustering methods have often been used to elucidate clusters in high dimensional medical data, even though reliance on a single algorithm is known to be problematic. In this paper, we present a methodology to determine a set of ‘core classes’... Read More about A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients.